blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2986316

EP2986316 - METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR PROPHYLAXIS OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.12.2023
Database last updated on 10.08.2024
FormerThe patent has been granted
Status updated on  23.12.2022
FormerGrant of patent is intended
Status updated on  18.08.2022
FormerExamination is in progress
Status updated on  26.07.2022
FormerGrant of patent is intended
Status updated on  19.06.2022
FormerExamination is in progress
Status updated on  19.10.2018
Most recent event   Tooltip19.04.2024Lapse of the patent in a contracting state
New state(s): IE		published on 22.05.2024  [2024/21]
Applicant(s)For all designated states
Immuron Limited
Unit 10, 25-37 Chapman Street
Blackburn North, Victoria 3130 / AU
[2017/26]
Former [2016/08]For all designated states
Immuron Limited
18 Kavanagh Street
Level 1
Southbank, Victoria 3006 / AU
Inventor(s)01 / LYRAS, Dena
65 Dresden Street
Heidelberg Heights, Victoria 3081 / AU
02 / HUTTON, Melanie
603/45 Claremont Street
South Yarra, Victoria 3141 / AU
03 / CUNNINGHAM, Bliss
14 Prospect Hill Crescent
Dandenong North, Victoria 3175 / AU
04 / LI, Lucy
5 Vaucluse Court
Wheelers Hill, Victoria 3150 / AU
05 / CARTER, Glen
12 Boathaven Road
Point Cook, Victoria 3030 / AU
06 / ROOD, Julian
16 Wilson Street
Bentleigh, Victoria 3204 / AU
 [2016/08]
Representative(s)Dr. Gassner & Partner mbB
Wetterkreuz 3
91058 Erlangen / DE
[2023/04]
Former [2016/08]Ehnis, Tobias, et al
Dr. Gassner & Partner mbB
Patentanwälte
Marie-Curie-Strasse 1
91052 Erlangen / DE
Application number, filing date14784945.917.04.2014
[2016/08]
WO2014AU00447
Priority number, dateAU2013090138619.04.2013         Original published format: AU 2013901386
[2016/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014169344
Date:23.10.2014
Language:EN
[2014/43]
Type: A1 Application with search report 
No.:EP2986316
Date:24.02.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 23.10.2014 takes the place of the publication of the European patent application.
[2016/08]
Type: B1 Patent specification 
No.:EP2986316
Date:25.01.2023
Language:EN
[2023/04]
Search report(s)International search report - published on:AU23.10.2014
(Supplementary) European search report - dispatched on:EP28.10.2016
ClassificationIPC:C07K16/12, A61K39/395, A61K39/40, A61P1/12, A61P31/04
[2016/48]
CPC:
C07K16/1282 (EP,US); A61K39/40 (US); A61K9/0053 (US);
A61P1/12 (EP); A61P31/04 (EP); C07K16/04 (US);
A61K2039/505 (EP,US); A61K2039/522 (EP,US); C07K2317/12 (EP,US);
C07K2317/76 (EP,US); Y02A50/30 (EP) (-)
Former IPC [2016/08]A61K39/395, A61K39/40, A61P1/12, A61P31/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/08]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG UND/ODER PROPHYLAXE VON CLOSTRIDIUM-DIFFICILE-VERMITTELTEN KRANKHEITEN[2016/08]
English:METHODS AND COMPOSITIONS FOR THE TREATMENT AND/OR PROPHYLAXIS OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE[2016/08]
French:MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT ET/OU LA PROPHYLAXIE D'UNE MALADIE ASSOCIÉE À CLOSTRIDIUM DIFFICILE[2016/08]
Entry into regional phase17.11.2015National basic fee paid 
17.11.2015Search fee paid 
17.11.2015Designation fee(s) paid 
17.11.2015Examination fee paid 
Examination procedure17.11.2015Examination requested  [2016/08]
18.05.2017Amendment by applicant (claims and/or description)
17.10.2018Despatch of a communication from the examining division (Time limit: M06)
29.04.2019Reply to a communication from the examining division
10.09.2019Despatch of a communication from the examining division (Time limit: M06)
16.04.2020Reply to a communication from the examining division
27.04.2022Cancellation of oral proceeding that was planned for 17.05.2022
17.05.2022Date of oral proceedings (cancelled)
20.06.2022Communication of intention to grant the patent
26.07.2022Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.08.2022Communication of intention to grant the patent
20.12.2022Fee for grant paid
20.12.2022Fee for publishing/printing paid
20.12.2022Receipt of the translation of the claim(s)
Opposition(s)26.10.2023No opposition filed within time limit [2024/01]
Fees paidRenewal fee
09.02.2016Renewal fee patent year 03
28.04.2017Renewal fee patent year 04
26.04.2018Renewal fee patent year 05
29.04.2019Renewal fee patent year 06
06.03.2020Renewal fee patent year 07
15.04.2021Renewal fee patent year 08
18.03.2022Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT25.01.2023
CZ25.01.2023
DK25.01.2023
EE25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SE25.01.2023
SI25.01.2023
SK25.01.2023
SM25.01.2023
IE17.04.2023
LU17.04.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
[2024/21]
Former [2024/11]AT25.01.2023
CZ25.01.2023
DK25.01.2023
EE25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SE25.01.2023
SI25.01.2023
SK25.01.2023
SM25.01.2023
LU17.04.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2024/08]AT25.01.2023
CZ25.01.2023
DK25.01.2023
EE25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
MC25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SE25.01.2023
SK25.01.2023
SM25.01.2023
LU17.04.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2024/04]AT25.01.2023
CZ25.01.2023
DK25.01.2023
EE25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SE25.01.2023
SK25.01.2023
SM25.01.2023
LU17.04.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/50]AT25.01.2023
CZ25.01.2023
DK25.01.2023
EE25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SE25.01.2023
SK25.01.2023
SM25.01.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/49]AT25.01.2023
CZ25.01.2023
DK25.01.2023
EE25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RO25.01.2023
RS25.01.2023
SE25.01.2023
SM25.01.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/48]AT25.01.2023
DK25.01.2023
EE25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RS25.01.2023
SE25.01.2023
SM25.01.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/46]AT25.01.2023
DK25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RS25.01.2023
SE25.01.2023
SM25.01.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/39]AT25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RS25.01.2023
SE25.01.2023
NO25.04.2023
GR26.04.2023
IS25.05.2023
PT25.05.2023
Former [2023/38]AT25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
PL25.01.2023
RS25.01.2023
SE25.01.2023
NO25.04.2023
GR26.04.2023
PT25.05.2023
Former [2023/37]AT25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
RS25.01.2023
SE25.01.2023
NO25.04.2023
GR26.04.2023
PT25.05.2023
Former [2023/36]AT25.01.2023
FI25.01.2023
HR25.01.2023
LT25.01.2023
LV25.01.2023
RS25.01.2023
SE25.01.2023
NO25.04.2023
PT25.05.2023
Former [2023/35]AT25.01.2023
HR25.01.2023
LT25.01.2023
RS25.01.2023
NO25.04.2023
PT25.05.2023
Former [2023/34]LT25.01.2023
RS25.01.2023
PT25.05.2023
Former [2023/33]LT25.01.2023
Documents cited:Search[IY]WO9902188  (UNIV ARIZONA [US]) [I] 9-12 * abstract * * page 19; example 3 * * page 7, line 23 - line 25 * [Y] 6,7,9-12;
 [XY]US6613329  (KINK JOHN A [US], et al) [X] 1,2,5,13-15 * column 134 - column 138; example 32 * [Y] 6,7,9-12;
 [XY]US2004126383  (THOMAS WILLIAM D [US], et al) [X] 1,2,5,13-15 * page 8, paragraph 0093 * [Y] 6,7,9-12;
 [XY]WO2010094970  (HEALTH PROT AGENCY [GB], et al) [X] 1,2,4,8,14,15 * abstract * * page 24; example 5 * * page 25 - page 26; example 7 * * page 28 - page 29 * * page 34; example 14 * * page 35; example 16 * * page 35; example 17 * [Y] 6,7,9-12;
 [XY]  - MAROZSAN ANDRE J ET AL, "Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies", THE JOURNAL OF INFECTIOUS DISEASES UNITED STATES 15 DEC 2010, INFECTIOUS DISEASES SOCIETY OF AMERICA, US, (20120901), vol. 206, no. 5, doi:10.1093/INFDIS/JIS416, ISSN 1537-6613, pages 706 - 713, XP009168808 [X] 1-5,8,14,15 * abstract * * table 2 * * figure 3 * * page 2, column l, paragraph 5 - column r, paragraph 3 * * table 1 * [Y] 6,7,9-12

DOI:   http://dx.doi.org/10.1093/infdis/jis416
 [XY]  - VAN DISSEL JAAP T ET AL, "Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: preclinical and preliminary clinical data", JOURNAL OF MEDICAL MICROBIOLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, GB, (20050201), vol. 54, no. 2, doi:10.1099/JMM.0.45773-0, ISSN 0022-2615, pages 197 - 205, XP009100058 [X] 1,2,5,13-15 * abstract * * page 199, column r, paragraph 4 * * page 200, column l, paragraph 1 * * page 200, column l, paragraph 2 - column r, paragraph 2 * * page 201, column r, paragraph 3 * [Y] 6,7,9-12

DOI:   http://dx.doi.org/10.1099/jmm.0.45773-0
 [XY]  - J Salcedo ET AL, "Intravenous immunoglobulin therapy for severe Clostridium diYcile colitis", Gut, (19970101), pages 366 - 370, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891485/pdf/v041p00366.pdf, (20161020), XP055312557 [X] 1,2,5,13-15 * abstract * * page 367, column r, paragraph 3 - page 368, column l, paragraph 1 * [Y] 6,7,9-12
 [XY]  - BABCOCK GREGORY J ET AL, "Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, (20061101), vol. 74, no. 11, doi:10.1128/IAI.00982-06, ISSN 0019-9567, pages 6339 - 6347, XP009109025 [X] 1,2,5,13-15 * abstract * * figures 4-5 * [Y] 6,7,9-12

DOI:   http://dx.doi.org/10.1128/IAI.00982-06
 [Y]  - G. L. MULVEY ET AL, "Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection", JOURNAL OF MEDICAL MICROBIOLOGY., GB, (20110407), vol. 60, no. 8, doi:10.1099/jmm.0.029835-0, ISSN 0022-2615, pages 1181 - 1187, XP055312598 [Y] 6,7,9-12 * abstract *

DOI:   http://dx.doi.org/10.1099/jmm.0.029835-0
 [A]  - GREG HUSSACK AND JAMSHID TANHA, "Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives", TOXINS, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL (MDPI) AG, CH, vol. 2, no. 5, doi:10.3390/TOXINS2050998, ISSN 2072-6651, (20100507), pages 998 - 1018, (20100507), XP002692188 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.3390/toxins2050998
International search[X]WO2012092469  (CANGENE CORP [CA], et al)
Examination   - C. H. Chilton ET AL, "Comparative proteomic analysis of Clostridium difficile isolates of varying virulence", Journal of Medical Microbiology, (20140120), vol. 63, no. Pt_4, doi:10.1099/jmm.0.070409-0, ISSN 0022-2615, pages 489 - 503, XP055513999

DOI:   http://dx.doi.org/10.1099/jmm.0.070409-0
    - P. Vohra ET AL, "Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile", Microbiology, GB, (20110217), vol. 157, no. 5, doi:10.1099/mic.0.046243-0, ISSN 1350-0872, pages 1343 - 1353, XP055514009

DOI:   http://dx.doi.org/10.1099/mic.0.046243-0
    - Eero Mattila ET AL, "A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: Efficacy and safety data of a prematurely interrupted trial", SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES., NO, (20080108), vol. 40, no. 9, doi:10.1080/00365540801964960, ISSN 0036-5548, pages 702 - 708, XP055311806

DOI:   http://dx.doi.org/10.1080/00365540801964960
    - MERRIGAN MICHELLE ET AL, "Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production", JOURNAL OF BACTERIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 192, no. 19, doi:10.1128/JB.00445-10, ISSN 0021-9193, (20101001), pages 4904 - 4911, (20100730), XP009140830

DOI:   http://dx.doi.org/10.1128/JB.00445-10
    - DAVID A BURNS ET AL, "Sporulation studies in", JOURNAL OF MICROBIOLOGICAL METHODS, ELSEVIER, AMSTERDAM, NL, vol. 87, no. 2, doi:10.1016/J.MIMET.2011.07.017, ISSN 0167-7012, (20110721), pages 133 - 138, (20110816), XP028308217

DOI:   http://dx.doi.org/10.1016/j.mimet.2011.07.017
by applicantUS4550019
 US4748018
 US6537500
 WO03080082
 US2004161427
 WO2004078209
 WO2006053383
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO., (1990), pages 1521 - 1712
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.